Novartis AG (NYSE:NVS) has been given an average rating of “Hold” by the eighteen ratings firms that are currently covering the stock. Two investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $80.42.

A number of brokerages recently issued reports on NVS. Zacks Investment Research upgraded shares of Novartis AG from a “strong sell” rating to a “hold” rating in a research note on Monday, May 1st. Vetr downgraded shares of Novartis AG from a “buy” rating to a “hold” rating and set a $78.32 price target for the company. in a research note on Tuesday, April 25th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis AG in a research note on Tuesday, March 14th. Barclays PLC began coverage on shares of Novartis AG in a research note on Tuesday, March 7th. They issued an “underweight” rating for the company. Finally, Societe Generale upgraded shares of Novartis AG from a “hold” rating to a “buy” rating and lifted their price target for the stock from $73.82 to $74.37 in a research note on Tuesday, March 7th.

WARNING: “Novartis AG (NVS) Given Average Rating of “Hold” by Brokerages” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/05/15/novartis-ag-nvs-given-average-rating-of-hold-by-brokerages.html.

Several hedge funds have recently modified their holdings of NVS. Howe & Rusling Inc. increased its stake in shares of Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock valued at $100,000 after buying an additional 882 shares in the last quarter. TCI Wealth Advisors Inc. increased its stake in shares of Novartis AG by 20.0% in the first quarter. TCI Wealth Advisors Inc. now owns 1,381 shares of the company’s stock valued at $103,000 after buying an additional 230 shares in the last quarter. Kernodle & Katon Asset Management Group LLC increased its stake in shares of Novartis AG by 3.4% in the first quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after buying an additional 49 shares in the last quarter. North Star Investment Management Corp. increased its stake in shares of Novartis AG by 50.3% in the first quarter. North Star Investment Management Corp. now owns 1,526 shares of the company’s stock valued at $113,000 after buying an additional 511 shares in the last quarter. Finally, Sowell Financial Services LLC bought a new stake in shares of Novartis AG during the fourth quarter valued at $116,000. Institutional investors and hedge funds own 9.82% of the company’s stock.

Shares of Novartis AG (NYSE:NVS) traded up 0.02% during midday trading on Monday, hitting $80.50. 1,839,838 shares of the stock traded hands. The company has a market cap of $190.43 billion, a price-to-earnings ratio of 30.26 and a beta of 0.73. The stock has a 50-day moving average of $75.52 and a 200-day moving average of $73.44. Novartis AG has a 52-week low of $66.93 and a 52-week high of $83.58.

Novartis AG (NYSE:NVS) last issued its quarterly earnings results on Tuesday, April 25th. The company reported $1.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. Novartis AG had a net margin of 13.80% and a return on equity of 15.37%. The company had revenue of $11.54 billion during the quarter, compared to the consensus estimate of $11.59 billion. During the same quarter in the previous year, the firm earned $1.17 earnings per share. The firm’s quarterly revenue was down .5% on a year-over-year basis. On average, equities analysts predict that Novartis AG will post $4.72 earnings per share for the current fiscal year.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

5 Day Chart for NYSE:NVS

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.